摘要
目的研究布地奈德混悬液阶梯雾化吸入对治疗婴幼儿哮喘的效果。方法将2004年12月至2005年12月在青岛大学医学院附属医院儿童哮喘中心收治的112例婴幼儿哮喘患儿,随机分为2组,布地奈德混悬液雾化吸入组48例(雾化组),确诊后采用布地奈德混悬液阶梯雾化吸入治疗;普米克气雾剂组64例,于确诊后采用普米克气雾剂+贮雾罐吸入治疗(气雾组),比较2组患儿临床症状评分、吸入依从性、就医次数和缓解期用药量。结果与气雾组比较,雾化组患儿的临床症状评分、就医次数和缓解期用药量明显低于气雾组(均P<0.05),吸入依从性明显高于气雾组(t=2.46,P<0.05)。结论布地奈德混悬液阶梯雾化吸入用于婴幼儿哮喘缓解期的治疗,具有临床控制率高、依从性好、方便、安全的特点,值得临床推广。
Objective To investigate the clinical effects of budesonide inhalation suspension step-nebulising inhalation therapy for infant asthma. Methods Totally 112 children with moderate or serious infant asthma from Dec 2004 to Dec 2005 were divided into two groups randomly. The budesonide inhalation suspension group （48 cases ） （ nebulising group ） was given budesonide inhalation suspension through jet nebulizer; pulmicort aerosol group （64 cases） （aerosol group） was given pulmicort aerosol through meterd dose inhalers （ MID ） ＋ spacer inhaler. The inhalation dosage of glucocorticosteroid decreased greatly according to the day-time and night-time clinical symptom score. The day-time and night-time clinical symptom score,compliance,attack times and inhalation dosage of glucocorticosteroid during remissive period were compared at every clinical visit or by telephone. All patients were followed up for 48 weeks. Results Compared to aerosol group,the clinical symptom score,inhalation dosage of glucocorticosteroid during remissive period and attack times were significantly lower in nebulising group （ P 〈 0. 05 ）. The compliance was significantly higher than that in aerosol group （ t = 2.46, P 〈 0. 05 ）. Conclusion Budesonide inhalation suspension step nebulising inhalation therapy for infant asthma is with high clinical control and high compliance and is convenient and safe, so it deserves to be performed in more patients.
出处
《中国实用儿科杂志》
CSCD
北大核心
2008年第8期609-611,共3页
Chinese Journal of Practical Pediatrics
关键词
布地奈德混悬液
雾化吸入
婴幼儿
哮喘
Budesonide inhalation suspension
Nebulising inhalation therapy
Infant
Asthma
